A stronger team
We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.
Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.
For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.
With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047
A stronger team
We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.
Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.
For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.
With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047
Latest news
View all
PharmNovo live at neurology theme event at RedEye
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read more
PharmNovo at the LSX Nordic Congress
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read more
17.5 MEUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read more
PharmNovo presenting at the Global Forum
On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more